Drug Delivery Technologies: Players, products & prospects to 2018
| Product Code | ESP00450 |
| Publication Date | June 2009 |
| Publisher | Espicom |
| Product Type | Report |
| Pages | 472 |
| ISBN Number | 978-1-85822-353-7 |
Drug Delivery Technologies: Players, products & prospects to 2018
Drug Delivery Technology: Assessing its potential
The time when advanced drug delivery was merely a means for profitable product life extension has gone. Drug delivery is now a major component of the pharmaceutical industry's future and critical to bringing novel therapies to market.
Indeed, without the ability to effectively deliver targeted drugs in therapeutically significant quantities, many of the gene-based agents in research would not be viable. Despite the importance of the sector, the pharmaceutical industry has not always been quick to embrace the full range of potential technologies and opportunities on offer.
With so many companies pursuing a wide range of research strategies, it is difficult for industry and commercial executives to get a balanced and independent overview of the competitive landscape.
That is why this major new 4-volume report, Drug Delivery Technologies: Players, Products and Prospects to 2018, is essential reading for everyone in the field, from niche technology specialists through to the investment community and the pharmaceutical industry itself.
By 2018 sales of products using the novel drug delivery technology assessed in this report could exceed US$58 billion
- This report provides a detailed insight into the current and future market for drug delivery technology and...
- Provides an overview of the marketplace, outlining current thinking on the technologies being researched and employed;
- Appraises currently available products which utilise drug delivery technology and assesses their future;
- Examines new product developments from major specialist drug delivery companies, critically analysing the prospects at the product level and forecasting sales;
- Allows ready comparison on different technologies within a company's portfolio;
- Provides a unique window on the sector's product launch timetable;
- Includes detailed appendices which allow at-a-glance reviews of the competitive landscape for both new and up and coming products.
Use this report to...
- Assess the strengths and weaknesses of competing products/technologies in the context of specific delivery sectors and development companies;
- Identify and review licencing and collaboration partners;
- Understand the merits and applications of the main approaches being researched;
- Quantify the commercial prospects for current and future products.
Volume I
Controlled-release Delivery
The controlled-release market was worth nearly US$21 billion globally in 2008. The sector is dominated by the launch of oral controlled-release formulations in key therapeutic areas such as the central nervous system, cardiovascular, metabolic and respiratory diseases. The growth of controlled-release delivery continues to be fuelled by line extensions helping to offset the impact of generic erosion. We estimate there are around 60 approved controlled-release products which will generate global sales of over US$21.5 billion in 2009, peaking at around US$29.5 billion in 2017 as products mature and face patent expiration leading to a decline in mature product sales to US$28.9 billion by 2018. In addition, we forecast that controlled-release products in development from 17 key companies could generate additional sales of over US$5.1 billion by 2018.
Impact on product lifecycles
Controlled-release technologies, possibly more than any other approved delivery systems, have been an important tool for pharmaceutical companies to protect their branded franchises from the ever increasing and competitive generic market. These formulations play a critical role in establishing a balanced portfolio of solid dosage products and may lead to enhanced efficacy and improved patient compliance. This leads to reductions in patient costs and extending product life-cycle management for both branded and generic pharmaceuticals.
In the past, pharmaceutical companies have tended to develop controlled-release formulations as immediate-release counterparts near patent expiration. This trend is reversing and companies are developing controlled-release formulations earlier in the product life-cycle and often launching multiple formulations (immediate release, controlled release/modified release, and delayed release) in parallel to expand the potential addressable patient population and gain a significant share of competitive market places.
This report answers key questions...
- Who will have launched novel products by 2018 and what technologies could they be using?
- Can market leaders such as ALZA and Elan maintain their status in controlled release in the face of growing competition?
- What obstacles must companies overcome to achieve full market potential?
- What strategies are proving most productive and for which companies?
- What will the product/company landscape look like in 2018?
- Volume II
- Nano-enabled Delivery
The true value of nanotechnology lies in its potential to improve the solubility and enhance the efficiency of product delivery. It has been successfully applied to the commercialisation of more than 30 drugs. Regulators have published numerous white papers on the topic and established Task Forces to monitor the progress and application of this technology although there are presently no regulations specific to nanomedicine or nano-enabled medical devices.
As the field of nanotechnology gains momentum and nano-enabled platforms emerge to address the industry's need for therapeutic, bioavailable and less toxic products, this market is expected to grow significantly over the next decade. Proof of concept data with novel compounds is accumulating and new formulations of old chemotherapeutic drugs offer the promise to revolutionise cancer therapies.
The potential of future applications:
- Tissue specific delivery - targeting the delivery of small and macro molecules across biological membranes such as the blood brain barrier for CNS drugs;
- Gene and vaccine delivery - non-viral delivery of genetic materials in nanohydrogels and nanocarriers with a high degree of efficiency and expression;
- Controlled-release devices - design of new nanoporous, bioerodible membranes;
- Increased biocompatibility - design of artificial surfaces engineering for medical and dental implants to by-pass unwanted inflammatory response;
- Improved drug bioavailability and solubility - through the engineering of drugs and reagents by nanostructuring;
- Applied diagnosis, etiology, prognosis and therapy (ADEPT) technology for the safe targeted delivery of toxic therapeutic drugs.
By 2018, the market could exceed US$13 billion
By 2018 the established nanotechnology product market will be US$10.2 billion. The market will mature as the number of marketed nano-enabled products doubles and second generation nanomedicines begin to emerge. These agents will address areas of high unmet clinical need and result in the formulation of approved and novel drugs which are safer, less toxic and more efficacious than first generation products.
By 2018 these second generation nanomedicines could generate sales of nearly US$2.9 billion and establish nanotechnology as an important tool in the industry's delivery armoury. A range of proprietary delivery platforms will utilise CaP technologies, FluidCrystals, micelles and polymeric nanoparticles to target a number of therapy areas such as CNS disorders, oncology and infectious diseases.
Volume III
Nucleic Acid Delivery
The nucleic acid delivery market is maturing with over 1,450 clinical trials underway worldwide. The majority of these are in early clinical development (approximately 60%) with just over 3% in Phase III trials. Our analysis indicates that up to 35 novel nucleic acid products could reach the market within our forecasting period (2008-2018). However the harsh economic environment may force companies to place promising drugs on hold as they focus on lead projects rather than multiple programmes. To date, only a handful of nucleic acid-based products have been approved for human prescription and these products rely on delivery technologies in one shape or form. We estimate the nucleic acid market was worth just over US$80 million globally in 2008.
By 2018 we anticipate the nucleic acid technology market will have matured as many of the late-stage clinical programmes come to fruition and drug delivery companies continue to overcome issues surrounding its safety and efficiency. The development of nucleic acid delivery systems will help to improve specificity whilst the development of novel polymers and lipopolymer complexes will help to carry larger DNA payloads in order to target cells and make multigene targeting a reality. We forecast that nucleic acid products in development from 11 key companies could generate additional sales of nearly US$2.3 billion by 2018. These products utilise a range of delivery platforms including viral to non-viral delivery systems, and cover gene therapies, gene agents and DNA vaccines for a variety of targets including cancer, cardiovascular and infectious diseases.
Catalysts for change
Improvements in our understanding into the underlying genetic causes of disease as well as the uptake of new mechanisms of modulating DNA such as RNA interference which will help to fuel market growth.
The development of a new generation of DNA vaccines that will provoke strong immunogenic responses and will help to determine whether this has been a sound investment for the pharma industry.
Launch of the first siRNA-based therapeutics (although progress has been dampened following the recent termination of Opko Health's leading eye treatment at the Phase III development stage). We anticipate companies will pursue other conditions such as infectious diseases and cancer where robust preclinical studies have already been performed and where drug delivery platforms have been adopted rather than the use of naked siRNAs.
- Which companies and products will dominate?
- This volume will tell you!
- Volume IV
- Targeted Delivery
By 2018, over 30 new products will be launched resulting in a global market for advanced targeted delivery products worth over US$8.5 billion.
Despite considerable advances in drug delivery technologies, there continues to be a high unmet clinical need for safer and better-tolerated drugs. Sub-optimal compliance and failure to persist with drug treatments are important determinants of therapeutic non-response and are of significant cost to healthcare providers. Advanced targeted drug delivery technologies will help to overcome some of these issues by improving pharmacokinetics, increasing tolerability and reducing dose-limiting off-target effects.
The need for targeted delivery platforms is increasing as patients and drug regulators seek to meet these challenges.
Current and future applications
Whilst the majority of targeted delivery systems under evaluation incorporate passive carrier systems, there will be a shift towards the use of actively targeted carriers to increase the therapeutic index of existing and new products. There are significant opportunities for future commercial developments within the pharmaceutical industry. These include:
- Cost-effective production of antibodies and antibody fragments for drug targeting;
- Development of new polymers and biopolymers that may be utilised in the safe and efficient targeted delivery of drugs and pro-drugs into host cells;
- Development and selective targeting of macromolecules to improve intracellular uptake and tissue specificity;
- Development of inactive pro-drugs for tissue specific release;
- Extended product life-cycles through the development of targeted formulations;
- Identification of new targeting ligands to improve the targeted delivery of small molecules and macromolecules;
- Utilisation of multiple targeting ligands to address the needs of patient sub-types;
- Combined technology platforms to develop targeted therapeutics and diagnostics in a single molecule.
A new generation of targeted delivery systems is under development to meet these needs which should provide greater control over the selective targeting of tissue, either with active moieties or inactive moieties which may be activated within the tissue by biological (enzymes), chemical (pH) or physical means (light, ultrasound) in order to release the active agent. The multitude of delivery platforms will lend themselves to the delivery of both small molecules and macromolecules and to a variety of target sites and delivery routes.
Unique company & technology evaluation
It is vital that management information is reliable, current and insightful. Today, product and company assessment must be seen in a wider competitive and market environment.
In this report we present a pr?(C)cis on each of the leading delivery specialists and potential new delivery platforms and have identified their key attributes, based on a number of criteria including:
- Proprietary delivery technology
- Applications of the delivery technology within the pharmaceutical industry
- Management/technical expertise of the delivery specialist
- Competition within the delivery technology sector
- Products in development/approved utilising the delivery technology
We have established a competitor ratio analysis based on each of the criteria mentioned above. Each criterion attracts an award of up to 10 points, with a maximum score of 50, thus enabling the establishment of an Espicom ""ranking table"" in each segment of the market, dependent on their relative attributes.
Multi-point evaluation and scoring assessment
Pharma drugs that utilise drug delivery systems have been evaluated based on a number of parameters, including:
- The technology
- Comparison of delivery platforms within each area including: activated, degradation or diffusion for controlled-release systems; nano-engineered (nanocrystals, nanoparticle, nanosuspension) or nanocarriers (carbon/ceramic, dendrimer, liposome, micelle, polymeric nanoparticles) for nano-enabled delivery; viral or non-viral platforms for nucleic acid delivery and active or passive platforms for targeted delivery systems
- The application of the technology within a number of therapy areas
- Route of delivery (oral, parenteral, transdermal, implantable), delivery of small molecules/macromolecules and vaccines, additional features such as bioerodible materials etc
- The current status of the technology in clinical development or following approval
- Number of approved and marketed products, clinical or preclinical development candidates, single or multiple products.
- Competition within the technology arena
- Alternative drug delivery systems to technologies under evaluation, advantages and disadvantages over competitors.
- The drug delivery specialist's expertise
- Number of drug delivery systems in development, strategic alliances, financial position, marketing presence.
- The product portfolio
- Drug delivery systems under evaluation, products in development, commercialisation/development partnerships.
- Potential drug sales
- Based on key events such as market, competition, patent expiry, time of entry into the market.
Contents
- Report Overview
- Controlled-Release Delivery technologies
- Nano-enabled Delivery technologies
- Nucleic Acid Delivery technologies
- targeted Delivery technologies
- Competitor Ratio Analysis Summary
- Executive Summary
- Introduction
- Overview of controlled-release delivery: past, present & future
- Leading controlled-release technology platforms & characteristics
- Controlled delivery profiles
- Drug release profiles
- Controlled-release delivery: motivators & resistors
- Overview of controlled-release delivery: past, present & future
- Motivators
- Controlled-Release technology motivators
- Resistors
- Controlled-Release technology resistors
- Controlled-release delivery: impact on product lifecycles
- Impact of reformulation on product life-cycle
- Controlled-Release Delivery
- Types of controlled-release delivery used by pharma industry
- Activated controlled-release delivery
- Activated controlled-release delivery - ALZA's OROS systems
- Degradation controlled-release delivery
- Degradation controlled-release delivery - SkyePharma's GEOMATRIX
- Diffusion controlled-release delivery
- Monolithic diffusion controlled-release delivery - LaboPharm's Contramid
- Reservoir diffusion controlled-release delivery - Impax' CMDS
- Combined controlled-release delivery - Flamel's Micropump
- Advantages and disadvantages of controlled-release platforms
- Current therapeutic application of controlled-release in drug delivery
- Leading brands that utilise controlled-release delivery
- Leading controlled-release approved drugs
- Future commercial applications & opportunities
- Strategies of Drug Delivery Companies
- Leading controlled-release drug delivery companies
- Leading controlled-release drug delivery companies
- Partnerships & acquisitions
- Strategic developmental & commercialisation partnerships
- Merger & acquisitions
- Recent partnerships & acquisitions in the controlled-release field
- Intellectual Property
- Controlled-Release patents
- Leading controlled-release drug delivery companies
- The Controlled-Release Market
- Now 2009
- Approved controlled-release product sales
- Future 2018
- Global controlled-release product sales
- Drug Delivery Technologies: Players, products & prospects to 2018
- Novel controlled-release product sales
- Now 2009
- Competitor Analysis
- Movers & Shakers: Cutting edge or losing their grip
- Movers & shakers in controlled-release drug delivery systems
- COMPANY PROFILES
- AlphaRx Corporation (www alpharx com)
- Proprietary delivery technology
- Applications in the pharma industry
- Management/technical expertise
- Competition within the delivery technology sector
- Products in development/approved utilising the delivery technology
- AlphaRx' product pipeline
- Sales forecasts of products utilising the delivery technology
- AlphaRx' drug delivery sales
- Competitor Ratio Analysis
- AlZA Corporation (www alza com)
- Proprietary delivery technology
- Applications in the pharma industry
- Management/technical expertise
- Competition within the delivery technology sector
- Products in development/approved utilising the delivery technology
- ALZA's product pipeline
- Sales forecasts of products utilising the delivery technology
- ALZA's drug delivery sales
- Competitor Ratio Analysis
- Antares pharma, INC. (www antarespharma com)
- Proprietary delivery technology
- Applications in the pharma industry
- Management/technical expertise
- Competition within the delivery technology sector
- Products in development/approved utilising the delivery technology
- Antares' product pipeline
- Sales forecasts of products utilising the delivery technology
- Antares' drug delivery sales
- Competitor Ratio Analysis
- Biovail Corporation (www Biovail com)
- Proprietary delivery technology
- Applications in the pharma industry
- Management/technical expertise
- Competition within the delivery technology sector
- Products in development/approved utilising the delivery technology
- Biovail's product pipeline
- Sales forecasts of products utilising the delivery technology
- Biovail's drug delivery sales
- Competitor Ratio Analysis
- Camurus AB (www camurus se)
- Proprietary delivery technology
- Camurus' FluidCrystal CR technology
- Applications in the pharma industry
- Management/technical expertise
- Competition within the delivery technology sector
- Drug Delivery Technologies: Players, products & prospects to 2018
- Products in development/approved utilising the delivery technology
- Camurus AB's product pipeline
- Sales forecasts of products utilising the delivery technology
- Camurus AB's drug delivery sales
- Competitor Ratio Analysis
- Cerulean pharma INC (www ceruleanrx com)
- Proprietary delivery technology
- Applications in the pharma industry
- Management/technical expertise
- Competition within the delivery technology sector
- Products in development/approved utilising the delivery technology
- Cerulean's product pipeline
- Sales forecasts of products utilising the delivery technology
- Competitor Ratio Analysis
- Cipher pharmaceuticals, INC. (www cipherpharma com)
- Proprietary delivery technology
- Applications in the pharma industry
- Management/technical expertise
- Competition within the delivery technology sector
- Products in development/approved utilising the delivery technology
- Cipher's product pipeline
- Sales forecasts of products utilising the delivery technology
- Cipher's drug delivery sales
- Competitor Ratio Analysis
- Debiopharm group (www debio com)
- Proprietary delivery technology
- Applications in the pharma industry
- Management/technical expertise
- Competition within the delivery technology sector
- Products in development/approved utilising the delivery technology
- Debiopharm's product pipeline
- Sales forecasts of products utilising the delivery technology
- DebioPharm's drug delivery sales
- Competitor Ratio Analysis
- DelSite Biotechnologies, INC. (www delsite com)
- Proprietary delivery technology
- Applications in the pharma industry
- Management/technical expertise
- Competition within the delivery technology sector
- Products in development/approved utilising the delivery technology
- DelSite's product pipeline
- Sales forecasts of products utilising the delivery technology
- Competitor Ratio Analysis
- Depomed, INC. (www depomedinc com)
- Proprietary delivery technology
- Applications in the pharma industry
- Management/technical expertise
- Competition within the delivery technology sector
- Products in development/approved utilising the delivery technology
- Depomed's product pipeline
- Sales forecasts of products utilising the delivery technology
- Drug Delivery Technologies: Players, products & prospects to 2018
- Depomed's product sales
- Competitor Ratio Analysis
- Durect Corporation (www Durect com)
- Proprietary delivery technology
- Applications in the pharma industry
- Management/technical expertise
- Competition within the delivery technology sector
- Products in development/approved utilising the delivery technology
- Durect's product pipeline
- Sales forecasts of products utilising the delivery technology
- Durect's product sales
- Competitor Ratio Analysis
- elan Corporation (www elan com)
- Proprietary delivery technology
- Applications in the pharma industry
- Management/technical expertise
- Competition within the delivery technology sector
- Products in development/approved utilising the delivery technology
- Elan's product pipeline
- Sales forecasts of products utilising the delivery technology
- Elan's drug delivery sales
- Competitor Ratio Analysis
- elite pharmaceuticals, INC. (www elitepharma com)
- Proprietary delivery technology
- Applications in the pharma industry
- Management/technical expertise
- Competition within the delivery technology sector
- Elite's product pipeline
- Sales forecasts of products utilising the delivery technology
- Elite's product sales
- Competitor Ratio Analysis
- endo pharmaceuticals, INC. (www endo com)
- Proprietary delivery technology
- Applications in the pharma industry
- Management/technical expertise
- Competition within the delivery technology sector
- Products in development/approved utilising the delivery technology
- Endo's product pipeline
- Sales forecasts of products utilising the delivery technology
- Endo's product sales
- Competitor Ratio Analysis
- ethypharm SA (www ethypharm com)
- Proprietary delivery technology
- Applications in the pharma industry
- Management/technical expertise
- Competition within the delivery technology sector
- Products in development/approved utilising the delivery technology
- Ethypharm's product pipeline
- Sales forecasts of products utilising the delivery technology
- Ethypharm's product sales
- Competitor Ratio Analysis
- Drug Delivery Technologies: Players, products & prospects to 2018
- eurand (www eurand com)
- Proprietary delivery technology
- Applications in the pharma industry
- Management/technical expertise
- Competition within the delivery technology sector
- Products in development/approved utilising the delivery technology
- Eurand's product pipeline
- Sales forecasts of products utilising the delivery technology
- Eurand's product sales
- Competitor Ratio Analysis
- Flamel technologies, INC. (www flamel com)
- Proprietary delivery technology
- Flamel's Medusa technology
- Flamel's Micropump technology
- Applications in the pharma industry
- Management/technical expertise
- Competition within the delivery technology sector
- Products in development/approved utilising the delivery technology
- Flamel's product pipeline
- Sales forecasts of products utilising the delivery technology
- Flamel's product sales
- Competitor Ratio Analysis
- glycologic, ltd (www glycologic co UK)
- Proprietary delivery technology
- Applications in the pharma industry
- Management/technical expertise
- Competition within the delivery technology sector
- Products in development/approved utilising the delivery technology
- Glycologic's product pipeline
- Sales forecasts of products utilising the delivery technology
- Competitor Ratio Analysis
- Kv pharmaceuticals, INC (www kvpharmaceutical com)
- Proprietary delivery technology
- Applications in the pharma industry
- Management/technical expertise
- Competition within the delivery technology sector
- Products in development/approved utilising the delivery technology
- KV's product pipeline
- Sales forecasts of products utilising the delivery technology
- Competitor Ratio Analysis
- labopharm, INC. (www labopharm com)
- Proprietary delivery technology
- Applications in the pharma industry
- Management/technical expertise
- Competition within the delivery technology sector
- Products in development/approved utilising the delivery technology
- Labopharm's product pipeline
- Sales forecasts of products utilising the delivery technology
- Labopharm's product sales
- Competitor Ratio Analysis
- lavipharm SA (www lavipharm com)
- Drug Delivery Technologies: Players, products & prospects to 2018
- Proprietary delivery technology
- Applications in the pharma industry
- Management/technical expertise
- Competition within the delivery technology sector
- Products in development/approved utilising the delivery technology
- Lavipharm's product pipeline
- Sales forecasts of products utilising the delivery technology
- Competitor Ratio Analysis
- Nano interface technology (www nanointerfacetech com)
- Proprietary delivery technology
- Applications in the pharma industry
- Management/technical expertise
- Competition within the delivery technology sector
- Products in development/approved utilising the delivery technology
- NITI's product pipeline
- Sales forecasts of products utilising the delivery technology
- Competitor Ratio Analysis
- octoplus N V. (www octoplus nl)
- Proprietary delivery technology
- Applications in the pharma industry
- Management/technical expertise
- Competition within the delivery technology sector
- Products in development/approved utilising the delivery technology
- OctoPlus' product pipeline
- Sales forecasts of products utilising the delivery technology
- OctoPlus' product sales
- Competitor Ratio Analysis
- penwest pharmaceuticals (www penw com)
- Proprietary delivery technology
- Applications in the pharma industry
- Management/technical expertise
- Competition within the delivery technology sector
- Products in development/approved utilising the delivery technology
- Penwest's product pipeline
- Sales forecasts of products utilising the delivery technology
- Penwest's product sales
- Competitor Ratio Analysis
- SColR pharma, INC. (www scolr com)
- Proprietary delivery technology
- Applications in the pharma industry
- Management/technical expertise
- Competition within the delivery technology sector
- Products in development/approved utilising the delivery technology
- SCOLR's product pipeline
- Sales forecasts of products utilising the delivery technology
- SCOLR's drug delivery sales
- Competitor Ratio Analysis
- Shire, plc (www shire com)
- Proprietary delivery technology
- Applications in the pharma industry
- Management/technical expertise
- Drug Delivery Technologies: Players, products & prospects to 2018
- Competition within the delivery technology sector
- Products in development/approved utilising the delivery technology
- Shire's product pipeline
- Sales forecasts of products utilising the delivery technology
- Shire's leading drug delivery product sales
- Competitor Ratio Analysis
- Skinvisible, INC. (www skinvisible com)
- Proprietary delivery technology
- Applications in the pharma industry
- Management/technical expertise
- Competition within the delivery technology sector
- Products in development/approved utilising the delivery technology
- Skinvisible's product pipeline
- Sales forecasts of products utilising the delivery technology
- Competitor Ratio Analysis
- Skyepharma (www skyepharma com)
- Proprietary delivery technology
- Applications in the pharma industry
- Management/technical expertise
- Competition within the delivery technology sector
- Products in development/approved utilising the delivery technology
- SkyePharma's product pipeline
- Sales forecasts of products utilising the delivery technology
- SkyePharma's product sales
- Competitor Ratio Analysis
- Spherics (www spherics com)
- Proprietary delivery technology
- Applications in the pharma industry
- Management/technical expertise
- Competition within the delivery technology sector
- Products in development/approved utilising the delivery technology
- Spheric's product pipeline
- Sales forecasts of products utilising the delivery technology
- Spheric's product sales
- Competitor Ratio Analysis
- watson pharmaceuticals (www watson com)
- Proprietary delivery technology
- Applications in the pharma industry
- Management/technical expertise
- Competition within the delivery technology sector
- Products in development/approved utilising the delivery technology
- Watson's product pipeline
- Sales forecasts of products utilising the delivery technology
- Watson's drug delivery sales
- Competitor Ratio Analysis
- Movers & Shakers: Cutting edge or losing their grip
- Appendix
- Global controlled-release approved drugs sales 2008-2018 (US$million)
- Appendix
- Global controlled-release developmental drugs sales 2008-2018 (US$million)
- Appendix
- Competitor Ratio Analysis Criteria
- Drug Delivery Technologies: Players, products & prospects to 2018
- Key Controlled-release delivery companies by 2015
- Competitor Ratio Analysis Criteria
- Bibliography
- Glossary
- Acronyms
- Endnotes
- Executive Summary
- Introduction
- Overview of nanotechnology: past, present & future
- Multifunctional nanotechnology platform
- Nanotechnology: motivators & resistors
- Motivators
- Nanotechnology motivators
- Resistors
- Nanotechnology resistors
- Nanomedicines, formulations and product regeneration
- Failure rates at each stage of clinical drug development
- Overview of nanotechnology: past, present & future
- Nanotechnology in Drug Delivery
- Core nanotechnology used by the pharma industry
- Nano-engineered drugs
- Nano-carriers
- Dendrimer structure
- Liposome structure
- Micelle structure
- Polymeric nanoparticle structure - Abraxane
- Current therapeutic applications of nanotechnology in drug delivery
- Leading brands that utilise nanotechnology delivery
- Nanotechnology-enabled approved drugs
- Future commercial applications & opportunities
- Strategies of Drug Delivery Companies
- Leading nanotechnology drug delivery companies
- Leading nanotechnology-enabled drug delivery companies
- Partnerships & acquisitions
- Strategic development & commercialisation partnerships and joint ventures
- Mergers, acquisitions, start ups & spin offs
- Recent partnerships & acquisitions in the nanotechnology field
- intellectual property
- Nanotechnology patents
- Leading nanotechnology drug delivery companies
- The Nanotechnology Market
- Now 2009
- Leading approved nano-enabled product sales
- Leading companies developing nano-enabled product sales
- Future 2018
- Novel nano-enabled product sales
- Global nano-enabled product sales
- Now 2009
- Competitor Analysis
- Movers & Shakers: Cutting edge or losing their grip
- Movers & shakers in nanotechnology drug delivery systems
- COMPANY PROFILES
- Abraxis Bioscience (www abraxisbio com)
- Drug Delivery Technologies: Players, products & prospects to 2018
- Proprietary delivery technology
- Abraxis Protosphere - nab technology
- Applications in the pharma industry
- Management/technical expertise
- Competition within the delivery technology sector
- Products in development/approved utilising the delivery technology
- Abraxis' product pipeline
- Sales forecasts of products utilising the delivery technology
- Abraxis' sales forecasts
- Competitor Ratio Analysis
- Access pharmaceuticals (www accesspharma com)
- Proprietary delivery technology
- ProLindac nanoparticulate prodrug
- Cobalamin coated nanoparticulates
- Applications in the pharma industry
- Management/technical expertise
- Competition within the delivery technology sector
- Products in development/approved utilising the delivery technology
- Access Pharmaceuticals product pipeline
- Sales forecasts of products utilising the delivery technology
- Access' sales forecasts
- Competitor Ratio Analysis
- AlphaRx Corporation (www alpharx com)
- Proprietary delivery technology
- Nanoparticle targeted delivery & uptake
- Applications in the pharma industry
- Management/technical expertise
- Competition within the delivery technology sector
- Products in development/approved utilising the delivery technology
- AlphaRx' product pipeline
- Sales forecasts of products utilising the delivery technology
- AlphaRx' pharmaceuticals sales
- Competitor Ratio Analysis
- AlZA Corporation (www alza com)
- Proprietary delivery technology
- Applications in the pharma industry
- Management/technical expertise
- Competition within the delivery technology sector
- Products in development/approved utilising the delivery technology
- Sales forecasts of products utilising the delivery technology
- ALZA's drug delivery sales
- Competitor Ratio Analysis
- Aphios Corporation (www aphios com)
- Proprietary delivery technology
- Applications in the pharma industry
- Management/technical expertise
- Competition within the delivery technology sector
- Products in development/approved utilising the delivery technology
- Aphios' product pipeline
- Sales forecasts of products utilising the delivery technology
- Competitor Ratio Analysis
- Drug Delivery Technologies: Players, products & prospects to 2018
- ApR Applied pharma Research (www apr com)
- Proprietary delivery technology
- Applications in the pharma industry
- Management/technical expertise
- Competition within the delivery technology sector
- Products in development/approved utilising the delivery technology
- APR's product pipeline
- Sales forecasts of products utilising the delivery technology
- Competitor Ratio Analysis
- BioSante pharmaceuticals (www biosantepharma com)
- Proprietary delivery technology
- Applications in the pharma industry
- Management/technical expertise
- Competition within the delivery technology sector
- Products in development/approved utilising the delivery technology
- BioSante's CaP product pipeline
- Sales forecasts of products utilising the delivery technology
- BioSante's drug delivery sales
- Competitor Ratio Analysis
- Calando pharmaceuticals (www. calandopharma com)
- Proprietary delivery technology
- Schematic of cyclodextrin polymeric nanoparticles
- Applications in the pharma industry
- Management/technical expertise
- Competition within the delivery technology sector
- Products in development/approved utilising the delivery technology
- Calando's product pipeline
- Sales forecasts of products utilising the delivery technology
- Calando's sales forecasts
- Competitor Ratio Analysis
- Camurus AB (www camurus se)
- Proprietary delivery technology
- Applications in the pharma industry
- Management/technical expertise
- Competition within the delivery technology sector
- Products in development/approved utilising the delivery technology
- Camurus AB's product pipeline
- Sales forecasts of products utilising the delivery technology
- Camurus AB's drug delivery sales
- Competitor Ratio Analysis
- Cerulean pharma INC (www ceruleanrx com)
- Proprietary delivery technology
- Applications in the pharma industry
- Management/technical expertise
- Competition within the delivery technology sector
- Products in development/approved utilising the delivery technology
- Cerulean's product pipeline
- Sales forecasts of products utilising the delivery technology
- Competitor Ratio Analysis
- Cytimmune Sciences INC (www cytimmune com)
- Proprietary delivery technology
- Drug Delivery Technologies: Players, products & prospects to 2018
- CytImmune's Colloidal Gold Nanoparticle Delivery
- Applications in the pharma industry
- Management/technical expertise
- Competition within the delivery technology sector
- Products in development/approved utilising the delivery technology
- CytImmune's' product pipeline
- Sales forecasts of products utilising the delivery technology
- CytImmune's sales forecasts
- Competitor Ratio Analysis
- elan Corporation (www elan com)
- Proprietary delivery technology
- Applications in the pharma industry
- Management/technical expertise
- Competition within the delivery technology sector
- Products in development/approved utilising the delivery technology
- Elan's NanoCrystal product portfolio
- Sales forecasts of products utilising the delivery technology
- Elan's drug delivery sales
- Competitor Ratio Analysis
- enzon pharmaceuticals, INC. (www enzon com)
- Proprietary delivery technology
- Applications in the pharma industry
- Management/technical expertise
- Competition within the delivery technology sector
- Products in development/approved utilising the delivery technology
- Enzon's product pipeline
- Sales forecasts of products utilising the delivery technology
- Enzon's targeted product sales
- Competitor Ratio Analysis
- gilead Sciences (www gilead com)
- Proprietary delivery technology
- Applications in the pharma industry
- Management/technical expertise
- Competition within the delivery technology sector
- Products in development/approved utilising the delivery technology
- Gilead Sciences' product pipeline
- Sales forecasts of products utilising the delivery technology
- Gilead Sciences' drug delivery sales
- Competitor Ratio Analysis
- introgen therapeutics (www introgen com)
- Proprietary delivery technology
- Applications in the pharma industry
- Management/technical expertise
- Competition within the delivery technology sector
- Products in development/approved utilising the delivery technology
- Introgen's product pipeline
- Sales forecasts of products utilising the delivery technology
- Introgen's sales forecasts
- Competitor Ratio Analysis
- Mersana therapeutics (www mersana com)
- Proprietary delivery technology
- Drug Delivery Technologies: Players, products & prospects to 2018
- Applications in the pharma industry
- Management/technical expertise
- Competition within the delivery technology sector
- Products in development/approved utilising the delivery technology
- Mersana's product pipeline
- Sales forecasts of products utilising the delivery technology
- Mersana's sales forecasts
- Competitor Ratio Analysis
- Nano interface technology (www nanointerfacetech com)
- Proprietary delivery technology
- Applications in the pharma industry
- Management/technical expertise
- Competition within the delivery technology sector
- Products in development/approved utilising the delivery technology
- NITI's product pipeline
- Sales forecasts of products utilising the delivery technology
- Competitor Ratio Analysis
- Nano S Biotechnology gmbh (www nano-s com)
- Proprietary delivery technology
- S-Layer Technology Platform
- Applications in the pharma industry
- Management/technical expertise
- Competition within the delivery technology sector
- Products in development/approved utilising the delivery technology
- Nano S' product pipeline
- Sales forecasts of products utilising the delivery technology
- Competitor Ratio Analysis
- NanoBio Corporation (www nanobio com)
- Proprietary delivery technology
- Applications in the pharma industry
- Management/technical expertise
- Competition within the delivery technology sector
- Products in development/approved utilising the delivery technology
- NanoBio's product pipeline
- Sales forecasts of products utilising the delivery technology
- NanoBio's drug delivery sales
- Competitor Ratio Analysis
- NanoBioMagnetics (www nanobmi com)
- Proprietary delivery technology
- Applications in the pharma industry
- Management/technical expertise
- Competition within the delivery technology sector
- Products in development/approved utilising the delivery technology
- NanoBioMagnetics' product pipeline
- Sales forecasts of products utilising the delivery technology
- Competitor Ratio Analysis
- Nanobiotix (www nanobiotix com)
- Proprietary delivery technology
- Applications in the pharma industry
- Management/technical expertise
- Competition within the delivery technology sector
- Drug Delivery Technologies: Players, products & prospects to 2018
- Products in development/approved utilising the delivery technology
- Nanobiotix' product pipeline
- Sales forecasts of products utilising the delivery technology
- Competitor Ratio Analysis
- NanoCarrier (www nanocarrier co jp)
- Proprietary delivery technology
- Micellar Nanoparticles
- Applications in the pharma industry
- Management/technical expertise
- Competition within the delivery technology sector
- Products in development/approved utilising the delivery technology
- NanoCarrier's product pipeline
- Sales forecasts of products utilising the delivery technology
- NanoCarrier's drug delivery sales
- Competitor Ratio Analysis
- Nanotechnology victoria, ltd (www nanovic com)
- Proprietary delivery technology
- Applications in the pharma industry
- Management/technical expertise
- Competition within the delivery technology sector
- Products in development/approved utilising the delivery technology
- NanoVic's product pipeline
- Sales forecasts of products utilising the delivery technology
- Competitor Ratio Analysis
- NanoMaterials technology (www nanomt com)
- Proprietary delivery technology
- High Gravity Controlled Precipitation (HCGP) of nanomaterials
- Applications in the pharma industry
- Management/technical expertise
- Competition within the delivery technology sector
- Products in development/approved utilising the delivery technology
- NanoMaterial's product pipeline
- Sales forecasts of products utilising the delivery technology
- Competitor Ratio Analysis
- Nanotherapeutics (www nanotherapeutics com)
- Proprietary delivery technology
- Applications in the pharma industry
- Management/technical expertise
- Competition within the delivery technology sector
- Products in development/approved utilising the delivery technology
- Nanotherapeutics' product pipeline
- Sales forecasts of products utilising the delivery technology
- Nanotherapeutics' drug delivery sales
- Competitor Ratio Analysis
- Novavax (www novavax com)
- Proprietary delivery technology
- Applications in the pharma industry
- Management/technical expertise
- Competition within the delivery technology sector
- Products in development/approved utilising the delivery technology
- Novavax's product pipeline
- Drug Delivery Technologies: Players, products & prospects to 2018
- Sales forecasts of products utilising the delivery technology
- Novavax's drug delivery sales
- Competitor Ratio Analysis
- Skyepharma (www skyepharma com)
- Proprietary delivery technology
- Applications in the pharma industry
- Management/technical expertise
- Competition within the delivery technology sector
- Products in development/approved utilising the delivery technology
- SkyePharma's product pipeline
- Sales forecasts of products utilising the delivery technology
- SkyePharma's product sales
- Competitor Ratio Analysis
- Spherics (www spherics com)
- Proprietary delivery technology
- Applications in the pharma industry
- Management/technical expertise
- Competition within the delivery technology sector
- Products in development/approved utilising the delivery technology
- Spheric's product pipeline
- Sales forecasts of products utilising the delivery technology
- Competitor Ratio Analysis
- Starpharma (www starpharma com)
- Proprietary delivery technology
- Dendrimer nanotechnology
- Applications in the pharma industry
- Management/technical expertise
- Competition within the delivery technology sector
- Products in development/approved utilising the delivery technology
- Starpharma's product pipeline
- Sales forecasts of products utilising the delivery technology
- Starpharma's product sales
- Competitor Ratio Analysis
- Movers & Shakers: Cutting edge or losing their grip
- Appendix
- Global nanotechnology approved drugs sales 2008-2018
- Appendix
- Global nanotechnology developmental drugs sales 2008-2018
- Appendix
- Competitor Ratio Analysis Criteria
- Key nanotechnology delivery companies by 2018
- Competitor Ratio Analysis Criteria
- Glossary
- Acronyms
- Bibliography
- Endnotes
- Executive Summary
- Introduction
- Overview of delivery technologies for genetic material: past, present & future
- Leading technology platforms for the delivery of genetic material
- Nucleic acid delivery: motivators & resistors
- Drug Delivery Technologies: Players, products & prospects to 2018
- Nucleic acid technology motivators
- Motivators
- Nucleic acid technology resistors
- Resistors
- Overview of delivery technologies for genetic material: past, present & future
- Advanced Nucleic Acid Delivery Technologies
- Types of nucleic acid-based products under development by the pharma industry
- viral vector delivery of nucleic acids
- Schematic of gene therapy utilising HVJ envelope - virosome
- Bacterial vector delivery of nucleic acids
- Non-viral vector delivery of nucleic acids
- Chemical Technologies
- Stable nucleic acid-lipid particles
- Targeted nanoparticles
- Physical Technologies
- Schematic of Zosano Pharma's Patch Technology
- Advantages and disadvantages of nucleic acid platforms
- Current therapeutic applications for the viral and non-viral delivery of nucleic acids
- Leading nucleic acid based products in development
- Nucleic acid-based approved/filed drugs
- Selection of gene therapies in clinical development
- Selection of RNA therapeutics in clinical development
- Selection of DNA vaccines in clinical development
- Future commercial applications & opportunities
- Strategies of Drug Delivery Companies
- Leading nucleic acid drug delivery companies
- Leading nucleic acid drug delivery specialists
- Partnerships & acquisitions
- Strategic developmental & commercialisation partnerships
- Mergers, acquisitions & joint ventures
- Recent partnerships & acquisitions in the nucleic acid field
- Intellectual Property
- Nucleic acid patents
- Leading nucleic acid drug delivery companies
- The Viral and Non-Viral Vector Delivery Market
- Now 2009
- Approved nucleic acid product sales
- Future 2018
- Novel nucleic acid product sales
- Global controlled release product sales
- Now 2009
- Competitor Analysis
- Movers & Shakers: Cutting edge or losing their grip
- Movers & shakers in nucleic acid drug delivery systems
- COMPANY PROFILES
- Alnylam pharmaceuticals (www alnylam com )
- Proprietary delivery technology
- Applications in the pharma industry
- Management/technical expertise
- Competition within the delivery technology sector
- Products in development/approved utilising the delivery technology
- Alnylam's product pipeline
- Sales forecasts of products utilising the delivery technology
- Alnylam's sales forecasts
- Drug Delivery Technologies: Players, products & prospects to 2018
- Competitor Ratio Analysis
- Alphavax, INC. (www alphavax com)
- Proprietary delivery technology
- The alphavaccine platform system
- Applications in the pharma industry
- Management/technical expertise
- Competition within the delivery technology sector
- Products in development/approved utilising the delivery technology
- AlphaVax' product pipeline
- Sales forecasts of products utilising the delivery technology
- AlphaVax' sales forecasts
- Competitor Ratio Analysis
- Altea therapeutics, INC (www alteatherapeutics com)
- Proprietary delivery technology
- Altea Therapeutics' Passport Patch
- Applications in the pharma industry
- Management/technical expertise
- Competition within the delivery technology sector
- Products in development/approved utilising the delivery technology
- Altea Therapeutics' product pipeline
- Sales forecasts of products utilising the delivery technology
- Competitor Ratio Analysis
- Ap pharma, INC (www appharma com)
- Proprietary delivery technology
- Applications in the pharma industry
- Management/technical expertise
- Competition within the delivery technology sector
- Products in development/approved utilising the delivery technology
- AP Pharma's product pipeline
- Sales forecasts of products utilising the delivery technology
- Competitor Ratio Analysis
- Armagen technologies (www armagen com)
- Proprietary delivery technology
- ArmaGen's BBB delivery technology
- Applications in the pharma industry
- Management/technical expertise
- Competition within the delivery technology sector
- Products in development/approved utilising the delivery technology
- ArmaGen Technologies' product pipeline
- Sales forecasts of products utilising the delivery technology
- Competitor Ratio Analysis
- BioDelivery Sciences international (www biodeliverysciences com)
- Proprietary delivery technology
- Bioral Technology
- Applications in the pharma industry
- Management/technical expertise
- Competition within the delivery technology sector
- Products in development/approved utilising the delivery technology
- BDSI's product pipeline
- Sales forecasts of products utilising the delivery technology
- Competitor Ratio Analysis
- Drug Delivery Technologies: Players, products & prospects to 2018
- Calando pharmaceuticals (www calandopharma com)
- Proprietary delivery technology
- Schematic of cyclodextrin polymeric nanoparticles
- Applications in the pharma industry
- Management/technical expertise
- Competition within the delivery technology sector
- Products in development/approved utilising the delivery technology
- Calando's product pipeline
- Sales forecasts of products utilising the delivery technology
- Calando's sales forecasts
- Competitor Ratio Analysis
- Cequent pharmaceuticals (www cequentpharma com)
- Proprietary delivery technology
- Application in the pharma industry
- Management/technical expertise
- Competition within the delivery technology sector
- Products in development/approved utilising the delivery technology
- Cequent's product pipeline
- Sales forecasts of products utilising the delivery technology
- Cequent's sales forecasts
- Competitor Ratio Analysis
- Copernicus therapeutics (www cgsys com)
- Proprietary delivery technology
- Uptake and trafficking of condensed nanoparticle DNA
- Applications in the pharma industry
- Management/technical expertise
- Competition within the delivery technology sector
- Products in development/approved utilising the delivery technology
- Copernicus' product pipeline
- Sales forecasts of products utilising the delivery technology
- Competitor Ratio Analysis
- Diatos SA (www diatos com)
- Proprietary delivery technology
- Applications in the pharma industry
- Management/technical expertise
- Competition within the delivery technology sector
- Products in development/approved utilising the delivery technology
- Diatos' product pipeline
- Sales forecasts of products utilising the delivery technology
- Competitor Ratio Analysis
- DoR Biopharma, INC (www dorbiopharma com)
- Proprietary delivery technology
- Applications in the pharma industry
- Management/technical expertise
- Competition within the delivery technology sector
- Products in development/approved utilising the delivery technology
- DOR's product pipeline
- Sales forecasts of products utilising the delivery technology
- Competitor Ratio Analysis
- expression genetics, INC (www egencorp com)
- Proprietary delivery technology
- Drug Delivery Technologies: Players, products & prospects to 2018
- TheraPlas Technology Platform
- Applications in the pharma industry
- Management/technical expertise
- Competition within the delivery technology sector
- Products in development/approved utilising the delivery technology
- EGEN's product pipeline
- Sales forecasts of products utilising the delivery technology
- EGEN's sales forecasts
- Competitor Ratio Analysis
- inovio Biomedical Corporation (www inovio com)
- Proprietary delivery technology
- Inovio's gene delivery platform
- Applications in the pharma industry
- Management/technical expertise
- Competition within the delivery technology sector
- Products in development/approved utilising the delivery technology
- Inovio's product pipeline
- Sales forecasts of products utilising the delivery technology
- Inovio's sales forecasts
- Competitor Ratio Analysis
- MaxCyte, INC (www maxcyte com)
- Proprietary delivery technology
- MaxCyte's GT exvivo cell loading system
- Applications in the pharma industry
- Management/technical expertise
- Competition within the delivery technology sector
- Products in development/approved utilising the delivery technology
- MaxCyte's product pipeline
- Sales forecasts of products utilising the delivery technology
- Competitor Ratio Analysis
- Nanotherapeutics (www nanotherapeutics com)
- Proprietary delivery technology
- Applications in the pharma industry
- Management/technical expertise
- Competition within the delivery technology sector
- Products in development/approved utilising the delivery technology
- Nanotherapeutics' product pipeline
- Sales forecasts of products utilising the delivery technology
- Competitor Ratio Analysis
- Neopharm (www neopharm com)
- Proprietary delivery technology
- Management/technical expertise
- Competition within the delivery technology sector
- Products in development/approved utilising the delivery technology
- NeoPharm's product pipeline
- Sales forecasts of products utilising the delivery technology
- Competitor Ratio Analysis
- Novagali pharma SA (www novagali com)
- Proprietary delivery technology
- Management/technical expertise
- Competition within the delivery technology sector
- Drug Delivery Technologies: Players, products & prospects to 2018
- Products in development/approved utilising the delivery technology
- Novagali's product pipeline
- Sales forecasts of products utilising the delivery technology
- Competitor Ratio Analysis
- oxford Biomedica (www oxfordbiomedica com)
- Proprietary delivery technology
- Management/technical expertise
- Competition within the delivery technology sector
- Products in development/approved utilising the delivery technology
- Oxford Biomedica's product pipeline
- Sales forecasts of products utilising the delivery technology
- Oxford Biomedica's sales forecasts
- Competitor Ratio Analysis
- pCi Biotech (www pcibiotech com)
- Proprietary delivery technology
- PCI enhances siRNA's gene silencing effect and improves gene delivery
- Applications in the pharma industry
- Potential applications for improving the delivery of a range of drug types
- Management/technical expertise
- Competition within the delivery technology sector
- Products in development/approved utilising the delivery technology
- PCI's product pipeline
- Sales forecasts of products utilising the delivery technology
- Competitor Ratio Analysis
- Silence therapeutics plc (www silence-therapeutics com)
- Proprietary delivery technology
- Applications in the pharma industry
- Management/technical expertise
- Competition within the delivery technology sector
- Products in development/approved utilising the delivery technology
- Silence Therapeutics' product pipeline
- Sales forecasts of products utilising the delivery technology
- Silence Therapeutics' sales forecasts
- Competitor Ratio Analysis
- targeted genetics Corporation (www targetedgenetics com)
- Proprietary delivery technology
- Applications in the pharma industry
- Management/technical expertise
- Competition within the delivery technology sector
- Products in development/approved utilising the delivery technology
- TGEN's product pipeline
- Sales forecasts of products utilising the delivery technology
- Targeted Genetics sales forecasts
- Competitor Ratio Analysis
- tekmira pharmaceuticals Corporation (www tekmirapharm com)
- Proprietary delivery technology
- Applications in the pharma industry
- Management/technical expertise
- Competition within the delivery technology sector
- Products in development/approved utilising the delivery technology
- Tekmira's product pipeline
- Drug Delivery Technologies: Players, products & prospects to 2018
- Sales forecasts of products utilising the delivery technology
- Tekmira's sales forecasts
- Competitor Ratio Analysis
- tissuegene, INC (www tissuegene com)
- Proprietary delivery technology
- Manufacturing TissueGene-C cell mediated gene therapies
- Applications in the pharma industry
- Application of TissueGene-C cell mediated gene therapy in orthopaedics
- Management/technical expertise
- Competition within the delivery technology sector
- Products in development/approved utilising the delivery technology
- TissueGene's product pipeline
- Sales forecasts of products utilising the delivery technology
- Competitor Ratio Analysis
- vical, INC. (www vical com)
- Proprietary delivery technology
- Schematic of p-DNA delivery and utilisation in DNA vaccines
- Applications in the pharma industry
- Management/technical expertise
- Competition within the delivery technology sector
- Products in development/approved utilising the delivery technology
- Vical's product pipeline
- Sales forecasts of products utilising the delivery technology
- Vical's sales forecasts
- Competitor Ratio Analysis
- Zosano pharma, INC (www zosanopharma com )
- Proprietary delivery technology
- ZP Patch Technology
- Applications in the pharma industry
- Management/technical expertise
- Competition within the delivery technology sector
- Products in development/approved utilising the delivery technology
- Zosano Pharma's product pipeline
- Sales forecasts of products utilising the delivery technology
- Competitor Ratio Analysis
- Movers & Shakers: Cutting edge or losing their grip
- Appendix
- Global nucleic acid approved drugs sales 2008-2018
- Appendix
- Global nucleic acid developmental drugs sales 2008-2018
- Appendix
- Competitor Ratio Analysis Criteria
- Key Nucleic acid delivery companies by 2018
- Competitor Ratio Analysis Criteria
- Glossary
- Acronyms
- Endnotes
- Executive Summary
- Introduction
- Overview of delivery technologies for targeted delivery: past, present & future
- Leading technology platforms for systemic targeted drug delivery
- Drug Delivery Technologies: Players, products & prospects to 2018
- Systemic targeted delivery: motivators & resistors
- Motivators
- Systemic targeted delivery technology motivators
- Resistors
- Systemic targeted delivery technology resistors
- Overview of delivery technologies for targeted delivery: past, present & future
- Targeted Delivery Technologies
- Types of systemic targeted delivery platform in development in the pharma industry
- targeting ligands
- Antibody fragment conjugate delivery
- Antibody-directed enzyme pro-drug targeted delivery
- Peptide-induced release for targeted delivery
- Small molecule conjugate delivery
- Nucleomic mediated targeted intranuclear delivery
- Cobalamin mediated targeted intracellular delivery
- Non-biological targeting platforms
- Magnetically targeted delivery
- Photosensitive targeted delivery
- Current therapeutic applications for systemic targeted delivery
- Leading systemic targeted products in development
- Approved systemic and targeted drugs
- Future commercial applications & opportunities
- Strategies of Drug Delivery Companies
- Leading targeted drug delivery companies
- Leading systemic targeted delivery specialists
- Partnerships & acquisitions
- Strategic alliances
- Strategic acquisitions
- Recent market activity in targeted delivery companies
- Intellectual Property
- Targeted drug delivery patents
- Leading targeted drug delivery companies
- The Targeted Delivery Market
- Now 2009
- Approved targeted delivery product sales
- Future 2018
- Global targeted-release product sales
- Novel targeted delivery product sales
- Now 2009
- Competitor Analysis
- Movers & Shakers: Cutting edge or losing their grip
- Movers & shakers in targeted drug delivery systems
- Abraxis Biosciences (www abraxisbio com)
- Proprietary delivery technology
- Abraxis Protosphere - nab technology
- Applications in the pharma industry
- Management/technical expertise
- Competition within the delivery technology sector
- Products in development/approved utilising the delivery technology
- Abraxis' product pipeline
- Sales forecasts of products utilising the delivery technology
- Abraxis' targeted sales forecasts
- Competitor Ratio Analysis
- Access pharmaceuticals (www accesspharma com)
- Drug Delivery Technologies: Players, products & prospects to 2018
- Proprietary delivery technology
- Cobalamin targeted delivery
- Schematic of targeted nanoparticle
- Targeted delivery of cancer subtypes via folate polymer, Vitamin B12 polymer and biotin polymers
- Applications in the pharma industry
- Management/technical expertise
- Competition within the delivery technology sector
- Products in development/approved utilising the delivery technology
- Access Pharmaceuticals' product pipeline
- Sales forecasts of products utilising the delivery technology
- Access Pharmaceuticals' sales forecasts
- Competitor Ratio Analysis
- AlZA Corporation (www alza com)
- Proprietary delivery technology
- Applications in the pharma industry
- Management/technical expertise
- Competition within the delivery technology sector
- Products in development/approved utilising the delivery technology
- ALZA's targeted product pipeline
- Sales forecasts of products utilising the delivery technology
- ALZA's drug delivery sales
- Competitor Ratio Analysis
- Armagen technologies (www armagen com)
- Proprietary delivery technology
- Applications in the pharma industry
- Management/technical expertise
- Competition within the delivery technology sector
- Products in development/approved utilising the delivery technology
- ArmaGen Technologies' product pipeline
- Sales forecasts of products utilising the delivery technology
- Competitor Ratio Analysis
- Avidimer therapeutics (www avidimer com)
- Proprietary delivery technology
- Targeted avidimer for methotrexate delivery
- Applications in the pharma industry
- Management/technical expertise
- Competition within the delivery technology sector
- Products in development/approved utilising the delivery technology
- Avidimer's product pipeline
- Sales forecasts of products utilising the delivery technology
- Competitor Ratio Analysis
- Calando pharmaceuticals (www calandopharma com)
- Proprietary delivery technology
- Schematic of Cyclosert technology
- Schematic of RONDEL technology
- Applications in the pharma industry
- Management/technical expertise
- Competition within the delivery technology sector
- Products in development/approved utilising the delivery technology
- Calando's product pipeline
- Sales forecasts of products utilising the delivery technology
- Drug Delivery Technologies: Players, products & prospects to 2018
- Calando's sales forecasts
- Competitor Ratio Analysis
- Cell therapeutics (www ctiseattle com)
- Proprietary delivery technology
- CTI's polyglutamate polymer technology
- Applications in the pharma industry
- Management/technical expertise
- Competition within the delivery technology sector
- Products in development/approved utilising the delivery technology
- CTI's product pipeline
- Sales forecasts of products utilising the delivery technology
- CTI's targeted drug delivery sales
- Competitor Ratio Analysis
- Cerulean pharma INC (www ceruleanrx com)
- Proprietary delivery technology
- Applications in the pharma industry
- Management/technical expertise
- Competition within the delivery technology sector
- Products in development/approved utilising the delivery technology
- Cerulean's product pipeline
- Sales forecasts of products utilising the delivery technology
- Competitor Ratio Analysis
- Copernicus therapeutics (www cgsys com)
- Proprietary delivery technology
- Applications in the pharma industry
- Management/technical expertise
- Competition within the delivery technology sector
- Products in development/approved utilising the delivery technology
- Copernicus' product pipeline
- Sales forecasts of products utilising the delivery technology
- Competitor Ratio Analysis
- Cytimmune Sciences INC (www cytimmune com)
- Proprietary delivery technology
- Applications in the pharma industry
- Management/technical expertise
- Competition within the delivery technology sector
- Products in development/approved utilising the delivery technology
- CytImmune's' product pipeline
- Sales forecasts of products utilising the delivery technology
- CytImmune's sales forecasts
- Competitor Ratio Analysis
- Diatos SA (www diatos com)
- Proprietary delivery technology
- Applications in the pharma industry
- Management/technical expertise
- Competition within the delivery technology sector
- Products in development/approved utilising the delivery technology
- Diatos' product pipeline
- Sales forecasts of products utilising the delivery technology
- Diatos' targeted drug delivery sales
- Competitor Ratio Analysis
- Drug Delivery Technologies: Players, products & prospects to 2018
- enzon pharmaceuticals, INC. (www enzon com)
- Proprietary delivery technology
- Applications in the pharma industry
- Management/technical expertise
- Competition within the delivery technology sector
- Products in development/approved utilising the delivery technology
- Enzon's product pipeline
- Sales forecasts of products utilising the delivery technology
- Enzon's targeted product sales
- Competitor Ratio Analysis
- endocyte INC. (www endocyte com)
- Proprietary delivery technology
- Applications in the pharma industry
- Management/technical expertise
- Competition within the delivery technology sector
- Products in development/approved utilising the delivery technology
- Endocyte's product pipeline
- Sales forecasts of products utilising the delivery technology
- Endocyte's targeted drug delivery sales
- Competitor Ratio Analysis
- eurand (www eurand com)
- Proprietary delivery technology
- Applications in the pharma industry
- Management/technical expertise
- Competition within the delivery technology sector
- Products in development/approved utilising the delivery technology
- Eurand's product pipeline
- Sales forecasts of products utilising the delivery technology
- Competitor Ratio Analysis
- immunogen (www immunogen com)
- Proprietary delivery technology
- Applications in the pharma industry
- Management/technical expertise
- Competition within the delivery technology sector
- Products in development/approved utilising the delivery technology
- ImmunoGen's product pipeline
- Sales forecasts of products utilising the delivery technology
- ImmunoGen's targeted delivery sales
- Competitor Ratio Analysis
- imaRx therapeutics (www imarx com)
- Proprietary delivery technology
- Applications in the pharma industry
- Management/technical expertise
- Competition within the delivery technology sector
- Products in development/approved utilising the delivery technology
- ImaRx' product pipeline
- Sales forecasts of products utilising the delivery technology
- Competitor Ratio Analysis
- NanoBioMagnetics, INC (www nanobmi com)
- Proprietary delivery technology
- Applications in the pharma industry
- Drug Delivery Technologies: Players, pr
- Movers & Shakers: Cutting edge or losing their grip